Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: A prospective cohort study

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Unge, Christian ^a   Södergård, Björn ^a   Marrone, Gaetano ^a   Thorson, Anna ^a   Lukhwaro, Abigael ^b   Carter, Jane ^b   Ilako, Festus ^b   Ekström, Anna Mia ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b AMREF HEALTH AFRICA   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POVERTY; PRESCRIPTION; PROSPECTIVE STUDY; STIGMA; URBAN POPULATION; AFRICA SOUTH OF THE SAHARA; HEALTH; RISK FACTOR; STATISTICAL MODEL;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RISK FACTORS; URBAN HEALTH;

EID: 78149439712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013613     Document Type: Article

References (52)

1. Riley LW, Ko AI, Unger A, Reis MG (2007) Slum health: diseases of neglected populations. BMC Int Health Hum Rights 7: 2.
2. Magadi MA, Zulu EM, Brockerhoff M (2003) The inequality of maternal health care in urban sub-Saharan Africa in the 1990s. Popul Stud (Camb) 57: 347-366.
3. Taffa N (2003) A comparison of pregnancy and child health outcomes between teenage and adult mothers in the slums of Nairobi, Kenya. Int J Adolesc Med Health 15: 321-329.
4. Kyobutungi C, Ziraba AK, Ezeh A, Ye Y (2008) The burden of disease profile of residents of Nairobi's slums: Results from a Demographic Surveillance System. Popul Health Metr 6: 1.
5. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Aids 14: 357-366.
6. Coetzee D, Boulle A, Hildebrand K, Asselman V, Van Cutsem G, et al. (2004) Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 18(Suppl 3): S27-31.
7. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. Aids 18: 887-895.
8. Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-224.
9. Bangsberg DR (2006) Less than 95% adherence to nonnucleoside reversetranscriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43: 939-941.
10. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
11. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. Aids 21: 965-971.
12. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, et al. (2006) Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. Aids 20: 223-231.
13. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Aids 15: 1181-1183.
14. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, et al. (2002) Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16: 1051-1058.
15. van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, et al. (2005) Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 10: 464-470.
16. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, et al. (2005) Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis 41: 108-111.
17. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-saharan Africa: a systematic review. PLoS Med 4: e298.
18. Unge C, Sodergard B, Ekstrom AM, Carter J, Waweru M, et al. (2009) Challenges for scaling up ART in a resource-limited setting: a retrospective study in Kibera, Kenya. J Acquir Immune Defic Syndr 50: 397-402.
19. Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, et al. (2010) Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS ONE 5: e10340.
20. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006) Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3: e438.
21. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a metaanalysis. Jama 296: 679-690.
22. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, et al. (2007) Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19: 658-665.
23. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, et al. (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12: 255-266.
24. Mannheimer SB, Mukherjee R, Hirschhorn LR, Dougherty J, Celano SA, et al. (2006) The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care 18: 853-861.
25. Simoni J, Kurth A, Pearson C, Pantalone D, Merrill J, et al. (2006) Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management. AIDS Behaviour 10: 227-245.
26. Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, et al. (1999) Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 29: 824-830.
27. Duong M, Piroth L, Peytavin G, Forte F, Kohli E, et al. (2001) Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis 33: 386-392.
28. Nieuwkerk PT, Oort FJ (2005) Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr 38: 445-448.
29. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, et al. (2001) A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 134: 968-977.
30. Chalker J, Wagner A, Tomson G, Laing R, Johnson K, et al. Urgent need for coordination in adopting standardized antiretroviral adherence performance indicators. J Acquir Immune Defic Syndr 53: 159-161.
31. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353: 487-497.
32. Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, et al. (2001) Limited patient adherence to highly active antiretroviral therapy for HIV- 1 infection in an observational cohort study. Arch Intern Med 161: 1962-1968.
33. Nilsson Schonnesson L, Diamond PM, Ross MW, Williams M, Bratt G (2006) Baseline predictors of three types of antiretroviral therapy (ART) adherence: a 2- year follow-up. AIDS Care 18: 246-253.
34. Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K (2008) Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 8: 265.
35. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, et al. (2001) The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 28: 232-239.
36. Massaquoi M, Zachariah R, Manzi M, Pasulani O, Misindi D, et al. (2009) Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Trans R Soc Trop Med Hyg 103: 594-600.
37. Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338: 1281-1292.
38. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services (2009) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,. December 1, 2009 ed. Pp 1-168.
39. Wang H, Zhou J, Huang L, Li X, Fennie KP, et al. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. J Clin Nurs 19: 380-388.
40. Frick PA, Lavreys L, Mandaliya K, Kreiss JK (2001) Impact of an alarm device on medication compliance in women in Mombasa, Kenya. Int J STD AIDS 12: 329-333.
41. Muhamadi L NX, Tumwesigye MN, Wabwire-Mangen F, Ekström AM, Peterson S, Pariyo G (2010) Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: policy challenges/bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral therapy (CD,350 cells/ microL) in eastern Uganda. Health Policy 97: 187-194.
42. Unge C, Johansson A, Zachariah R, Some D, Van Engelgem I, et al. (2008) Reasons for unsatisfactory acceptance of antiretroviral treatment in the urban Kibera slum, Kenya. AIDS Care 20: 146-149.
43. Nachega JB, Leisegang R, Bishai D, Nguyen H, Hislop M, et al. Association ofantiretroviral therapy adherence and health care costs. Ann Intern Med 152: 18-25.
44. Zachariah R, Van Engelgem I, Massaquoi M, Kocholla L, Manzi M, et al. (2008) Payment for antiretroviral drugs is associated with a higher rate of patients lost to follow-up than those offered free-of-charge therapy in Nairobi, Kenya. Trans R Soc Trop Med Hyg 102: 288-293.
45. Bangsberg DR, Deeks SG Spending more to save more: interventions to promote adherence. Ann Intern Med 152: 54-56 W-13.
46. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, et al. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 14: 778-784.
47. Diabate S, Alary M, Koffi CK (2007) Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire. AIDS 21: 1799-1803.
48. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, et al. (2009) Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 6: e11.
49. Brinkhof MW, Pujades-Rodriguez M, Egger M (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 4: e5790.
50. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, et al. (2008) Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 47: 101-107.
51. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, et al. (2007) True outcomes for patients on antiretroviral therapy who are ''lost to follow-up'' in Malawi. Bull World Health Organ 85: 550-554.
52. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2009) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.